Sign in

Michael Okudovich

Senior Research Analyst at Maxim Group

Michael Okunewitch is a Senior Research Analyst at Maxim Group, specializing in equity research with coverage across a broad range of public companies including high-profile names such as Nvidia, Tesla, Amazon, and Alibaba, as well as smaller firms like Lexaria Bioscience. He has issued over 270 stock ratings since 2022, with the majority being 'Buy', and achieved his highest single-rating success with a 350% return on Lexaria Bioscience; overall, his ratings have a 34% success rate and an average return of -14.1%. Okunewitch began his analyst career prior to joining Maxim Group, where he has grown to hold a senior analyst role, and is recognized on research platforms such as TipRanks. He holds securities industry credentials, including applicable FINRA registrations, and is noted for deep sector knowledge and rigorous analytical methodology.

Michael Okudovich's questions to MediWound (MDWD) leadership

Michael Okudovich's questions to MediWound (MDWD) leadership • Q2 2025

Question

Michael Okudovich of Maxim Group questioned the progress of patient enrollment in the EscharEx VALUE study, the strategic benefit of collaborating with numerous wound care product companies, and which regions are most underserved by current NexoBrid supply.

Answer

CEO Ofer Gonen stated that enrollment is progressing well, with most U.S. sites active and European sites now being activated. EVP Barry Wolfferson added that collaborating with multiple companies demonstrates that EscharEx is effective with any standard-of-care product. Gonen noted that while demand for NexoBrid is substantial across all regions, the company is currently supply-constrained and will have better clarity once the new facility is online.

Ask Fintool Equity Research AI